From TD50 to Benchmark Dose in Nitrosamine Risk Assessment: Evidence from N-Nitrosotrimetazidine Carcinogenicity and TGR Mutation Data.
Melanie Foucaud Leheup, George E. Johnson, David Kirkland, Alice Griffon, Richard John Weaver, Flavia Pasello dos Santos, Stefan O. Mueller
This paper evaluates the carcinogenic risk of N-Nitrosotrimetazidine using in vitro and in vivo studies, deriving a benchmark dose and tumor dose to refine acceptable intake limits.
bioRxiv · Aug 27, 2026 · PreprintPharmacology & Toxicology